ArticleLipids in health and disease2025
High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCirculating PCSK9 concentrations have been linked to various metabolic disorders, with evidence suggesting sex-specific differences-stronger associations in women and inconsistent findings in men.
methodsThis study enrolled 7,950 participants from the Taiwan Biobank. Associations of PCSK9 concentration with insulin resistance (IR), metabolic syndrome (MetS), diabetes mellitus (DM), and long-term outcomes were analyzed. Anthropometric, biochemical, and hematologic parameters were examined in a subgroup of 6,478 participants, and 4,185 participants underwent abdominal sonography for the assessment of metabolic dysfunction-associated steatotic liver disease (MASLD).
resultsIncreasing PCSK9 concentrations and quartiles were significantly associated with older age, female sex, adverse cardiometabolic traits, and several hematological parameters. Higher hematocrit count, higher triglyceride, low-density lipoprotein cholesterol, fasting plasma glucose, and gamma-glutamyl transferase concentrations, and lower total bilirubin concentrations were independently associated with high PCSK9 concentration, with these associations being more pronounced among female participants. Higher platelet count was independently associated with high PCSK9 concentration only in female participants. Odds ratios for IR, MetS, DM, and MASLD increased progressively across PCSK9 quartiles, with stronger associations in women. Kaplan-Meier survival and Cox regression analyses indicated associations of high PCSK9 concentration with higher all-cause, non-cardiovascular, and cancer mortalities, especially in women.
conclusionHigh circulating PCSK9 concentration is independently associated with increased risks of IR, MetS, DM, MASLD, and all-cause and cancer mortality, indicating poor metabolic profiles and outcomes in the Taiwanese population. These associations are stronger in women, highlighting the importance of sex-specific risk evaluation in metabolic diseases and long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.